Decreased ipsilateral [123I]iododexetimide binding to cortical muscarinic receptors in unilaterally 6-hydroxydopamine lesioned rats

Nuclear Medicine and Biology

Volumn 41, Issue 1, 2014, Pages 90-95

  Knol, Remco J J ^a,b,c   de Bruin, Kora ^a   Opmeer, Brent ^d   Voorn, Pieter ^b,e   Jonker, Allert J ^b,e   van Eck Smit, Berthe L F ^a   Booij, Jan ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Graduate School of Neurosciences   (Netherlands)

^c Medical Centre Alkmaar   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

6 hydroxydopamine; Cholinergic; Dexetimide; Lewy body disorders; Parkinson's disease; Rats

Indexed keywords

IODINE IODODEXETIMIDE I 123; MUSCARINIC RECEPTOR; OXIDOPAMINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 4-IODODEXETIMIDE; DEXETIMIDE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOWN REGULATION; DRUG RECEPTOR BINDING; HIPPOCAMPUS; IN VIVO STUDY; MALE; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; POSTSYNAPTIC POTENTIAL; PROTEIN DEPLETION; PROTEIN DETERMINATION; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBCORTEX; ANIMAL; BRAIN; DIAGNOSTIC IMAGING; DRUG EFFECT; METABOLISM; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; WISTAR RAT;

6-HYDROXYDOPAMINE; 6-OHDA; ACETYLCHOLINE; ACETYLCHOLINESTERASE INHIBITOR; ACH; ACHEI; AD; ALZHEIMER'S DEMENTIA; BASAL NUCLEUS OF MEYNERT; CHOLINERGIC; DEMENTIA WITH LEWY BODIES; DEXETIMIDE; DLB; HC-3; HEMICHOLINIUM-3; LEWY BODY DISORDERS; MEDIAL FOREBRAIN BUNDLE; MFB; NBM; PARKINSON'S DISEASE; PARKINSON'S DISEASE RELATED DEMENTIA; PD; PDD; PET; POSITRON EMISSION TOMOGRAPHY; QNB; QUINUCLIDINYL BENZILATE; RATS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SPECT;

ANIMALS; BRAIN; DEXETIMIDE; MALE; OXIDOPAMINE; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, MUSCARINIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

MLCS; MLOWN;

EID: 84888347516     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.10.003     Document Type: Article

References (41)

1. Buter T.C., van den Hout A., Matthews F.E., Larsen J.P., Brayne C., Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008, 70:1017-1022.
2. Lippa C.F., Duda J.E., Grossman M., Hurtig H.I., Aarsland D., Boeve B.F., et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007, 68:812-819. DLB/PDD Working Group.
3. Caballol N., Martí M.J., Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007, 22(Suppl 17):S358-S366.
4. Wolters EC, van Laar T, Berendse HW. Parkinsonism and related disorders. VU University Press; 2007, p. 191-201.
5. Zurkovsky L., Bychkov E., Tsakem E.L., Siedlecki C., Blakely R.D., Gurevich E.V. Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice. Dis Model Mech 2013, 6:171-183.
6. Bohnen N.I., Müller M.L.T.M., Kotagal V., Koeppe R.A., Kilbourn M.R., Gilman S., et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012, 32:1609-1617.
7. Bosboom J.L.W., Stoffers D., Wolters E.C. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 2004, 111:1303-1315.
8. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003, 2:229-237.
9. Ballard C., Piggott M., Johnson M., Cairns N., Perry R., McKeith I., et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000, 48:868-876.
10. Candy J.M., Perry R.H., Perry E.K., Irving D., Blessed G., Fairbairn A.F., et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci 1983, 59:277-289.
11. Nakano I., Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984, 15:415-418.
12. Dubois B., Danzé F., Pillon B., Cusimano G., Lhermitte F., Agid Y. Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 1987, 22:26-30.
13. Katzenschlager R, Sampaio C, Costa J, Lees A: Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003:CD003735.
14. Emre M., Aarsland D., Albanese A., Byrne E.J., Deuschl G., De Deyn P.P., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518.
15. McKeith I., Mintzer J., Aarsland D., Burn D., Chiu H., Cohen-Mansfield J., et al. International Psychogeriatric Association expert meeting on DLB: dementia with Lewy bodies. Lancet Neurol 2004, 3:19-28.
16. Klein J.C., Eggers C., Kalbe E., Weisenbach S., Hohmann C., Vollmar S., et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010, 74:885-892.
17. Colloby S.J., Pakrasi S., Firbank M.J., Perry E.K., Piggott M.A., Owens J., et al. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R, R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage 2006, 33:423-429.
18. Claus J.J., Dubois E.A., Booij J., Habraken J., de Munck J.C., van Herk M., et al. Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography. Eur J Nucl Med 1997, 24:602-608.
19. 123I]-IDEX SPECT study. Psychopharmacology (Berl) 2001, 156:53-57.
20. Boundy K.L., Barnden L.R., Rowe C.C., Reid M., Kassiou M., Katsifis A.G., et al. Human dosimetry and biodistribution of iodine-123-iododexetimide: a SPECT imaging agent for cholinergic muscarinic neuroreceptors. J Nucl Med 1995, 36:1332-1338.
21. 123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem 1989, 32:1057-1062.
22. Schwarting R.K., Huston J.P. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 1996, 49:215-266.
23. Araki T., Tanji H., Fujihara K., Kato H., Imai Y., Mizugaki M., et al. Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats. J Neural Transm 2000, 107:873-884.
24. Muma N.A., Lee J.M., Gorman L., Heidenreich B.A., Mitrovic I., Napier T.C. 6-Hydroxydopamine-induced lesions of dopaminergic neurons alter the function of postsynaptic cholinergic neurons without changing cytoskeletal proteins. Exp Neurol 2001, 168:135-143.
25. van de Witte S.V., Drukarch B., Stoof J.C., Voorn P. Priming with L-DOPA differently affects dynorphin and substance P mRNA levels in the striatum of 6-hydroxydopamine-lesioned rats after challenge with dopamine D1-receptor agonist. Brain Res Mol Brain Res 1998, 61:219-223.
26. Habraken J.B., De Bruin K., Shehata M., Booij J., Bennink R., van Eck Smit B.L., et al. Evaluation of high-resolution pinhole SPECT using a small rotating animal. J Nucl Med 2001, 42:1863-1869.
27. Booij J, Andringa G, Rijks LJ, Vermeulen RJ, De Bruin K, Boer GJ, et al. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997; 27:183-90.
28. Booij J., de Bruin K., Habraken J.B.A., Voorn P. Imaging of dopamine transporters in rats using high-resolution pinhole single-photon emission tomography. Eur J Nucl Med Mol Imaging 2002, 29:1221-1224.
29. Knol R.J.J., de Bruin K., de Jong J., van Eck-Smit B.L.F., Booij J. In vitro and ex vivo storage phosphor imaging of short-living radioisotopes. J Neurosci Methods 2008, 168:341-357.
30. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press.
31. Zuch C.L., Nordstroem V.K., Briedrick L.A., Hoernig G.R., Granholm A.C., Bickford P.C. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol 2000, 427:440-454.
32. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatr 1997, 62:133-140.
33. Morgan S., Kemp P., Booij J., Costa D.C., Padayachee S., Lee L., et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatr 2012, 83:1063-1070.
34. van de Giessen E., la Fleur S.E., de Bruin K., van den Brink W., Booij J. Free-choice and no-choice high-fat diets affect striatal dopamine D2/3 receptor availability, caloric intake, and adiposity. Obesity 2012, 20:1738-1740.
35. Crunelle CL, van de Giessen E, Schulz S, Vanderschuren LJMJ, de Bruin K, van den Brink W, et al. Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability. Addict Biol 2011; Sep 29. doi: 10.1111/j.1369-1600.2011.00369.x.
36. Mash D.C., Potter L.T. Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience 1986, 19:551-564.
37. Fage D., Guerin B., Feuerstein C., Demenge P., Scatton B. Time course of the changes in striatal acetylcholine levels induced by pergolide and haloperidol after lesion of the nigrostriatal dopaminergic pathways in the rat. Brain Res 1984, 310:379-383.
38. Cao F., Luo F., Chen L., Chen H., Wei G., Cai J., et al. Experimental study on dynamic regulation of acetylcholine in striatum of rat parkinson disease model and behavior observation. J Huazhong Univ Sci Technol [Med Sci] 2012, 32:732-736.
39. Liskowsky D.R., Potter L.T. Muscarine-binding sites localized to cortical dopamine terminals. Neurosci Lett 1985, 58:229-233.
40. 125I]iododexetimide to muscarinic brain receptors. Nucl Med Biol 1998, 25:777-780.
41. Tayebati S.K., Di Tullio M.A., Amenta F. Muscarinic cholinergic receptor subtypes in cerebral cortex of Fisher 344 rats: a light microscope autoradiography study of age-related changes. Mech Ageing Dev 2006, 127:115-122.